Rocket Pharmaceuticals, Inc. Convertible Notes Payable, Current
Rocket Pharmaceuticals, Inc. (RCKT) had Convertible Notes Payable, Current of $0 as of 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Notes Payable, Current
us-gaap:ConvertibleNotesPayableCurrent · last filed 2022-02-28
- 2021-12-31: Convertible Notes Payable, Current $0.00.
- 2021-09-30: Convertible Notes Payable, Current $0.00.
- 2021-06-30: Convertible Notes Payable, Current $5.10M.
- 2021-03-31: Convertible Notes Payable, Current $4.99M.
| Period end | Convertible Notes Payable, Current |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-05 |
| 2021-06-30 | $5.10M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $4.99M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $4.88M 10-K · filed 2022-02-28 |
| 2020-09-30 | $4.76M 10-Q · filed 2020-11-06 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-01 |
| 2014-12-31 | $1.54M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |